Windtree Therapeutics Inc. entered into Note Purchase Agreements on June 24, 2025, with two purchasers. The company issued Convertible Promissory Notes worth $58,140 and $116,279 to the purchasers for $50,000 and $100,000, respectively. The Notes can convert to shares at $0.587 per share. Additionally, purchasers received warrants for $37,500 and $75,000 worth of shares, exercisable at the same price per share. The transactions raised $150,000 in gross proceeds to fund operational expenses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.